Abstract: A power generation facility in an embodiment includes: a boiler; a high-pressure turbine to which steam generated in the boiler is introduced; a low-pressure turbine provided downstream of the high-pressure turbine; and a condenser that condenses steam discharged from the low-pressure turbine. The power generation facility further includes: a feed pipe that leads feedwater in the condenser to the boiler; a heat storage and steam generation device that has a heat storage function that uses surplus energy generated in an own system to store heat, and a steam generation function that has part of feedwater led by the feed pipe introduced thereinto and turns the feedwater into steam by the stored heat; and a steam supply pipe that supplies steam generated in the heat storage and steam generation device to an own system.

Abstract: A power control apparatus of an embodiment controls power to be output to a power system from a power station including a power generation unit, and a power storage unit. The power control apparatus includes a power generation control unit, a power storage control unit, and a cooperation control unit. The power generation control unit controls an output of the power generation unit based on a power generation set value. The power storage control unit controls an output of the power storage unit based on a power storage set value. The cooperation control unit outputs the power generation set value to the power generation control unit and outputs the power storage set value to the power storage control unit based on a power demand amount of the power system so as to make the power generation unit and the power storage unit operate in a cooperative manner.

Abstract: In one embodiment, a power generation planning support apparatus includes an acquiring module configured to acquire a physical quantity that represents a startup condition of a turbine. The apparatus further includes a first storage module configured to store first information that represents a relationship between a startup schedule of the turbine and the physical quantity. The apparatus further includes a predicting module configured to predict the startup schedule of the turbine, based on the physical quantity acquired by the acquiring module and the first information stored in the first storage module. The apparatus further includes an outputting module configured to output the startup schedule predicted by the predicting module.

Abstract: In one embodiment, a power generation planning support apparatus includes an acquiring module configured to acquire a physical quantity that represents a startup condition of a turbine. The apparatus further includes a first storage module configured to store first information that represents a relationship between a startup schedule of the turbine and the physical quantity. The apparatus further includes a predicting module configured to predict the startup schedule of the turbine, based on the physical quantity acquired by the acquiring module and the first information stored in the first storage module. The apparatus further includes an outputting module configured to output the startup schedule predicted by the predicting module.

Abstract: According to one embodiment, a controlling apparatus is a controlling apparatus to control a combined cycle power plant that includes at least a plurality of units, each of the units including a gas turbine; an heat recovering steam generator that recovers heat of exhaust gas from the gas turbine and generates steam from an incorporated drum; and a turbine bypass regulating valve that sends the steam generated from the drum while keeping a predetermined pressure, and comprises a steam header unit that merges together the steam generated from a plurality of the drums; and a steam turbine to which the steam in the steam header unit is supplied. The controlling apparatus comprising a controlling unit that controls a plurality of the turbine bypass regulating valves based on a steam pressure detected in the steam header unit when the plurality of the units are linked.

Abstract: Disclosed is a monoclonal antibody which specifically reacts with active human ceruloplasmin as well as a method for diagnosing Wilson's disease using the same. The monoclonal antibody of the present invention specifically reacts with active human ceruloplasmin, it neutralizes the peroxidase activity of the active human ceruloplasmin upon binding thereto, and it does not specifically react with inactive human ceruloplasmin.

Abstract: Disclosed is a monoclonal antibody which specifically reacts with active human ceruloplasmin as well as a method for diagnosing Wilson's disease using the same. The monoclonal antibody of the present invention specifically reacts with active human ceruloplasmin, it neutralizes the peroxidase activity of the active human ceruloplasmin upon binding thereto, and it does not specifically react with inactive human ceruloplasmin.

Abstract: The process for producing mureidomycin A, B, C or D or a salt thereof by cultivating Streptomyces flavidovirens SANK 60486, FERM BP-1347, in a culture medium therefor and isolating mureidomycin A, B, C or D or a salt thereof from the cultured broth.

Abstract: New antibiotics of the mureidomycin group have the formula ##STR1##wherein X represents the group ##STR2##and wherein R represents hydrogen, an alkyl group having from 1 to 10 carbon atoms, an alkenyl group having from 2 to 7 carbon atoms, an alkynyl group having from 3 to 7 carbon atoms, an aryl group having from 6 to 10 carbon atoms, an aralkyl group having from 7 to 10 carbon atoms, or one of the said aryl or aralkyl groups substituted with at least one substituent selected from halogen and alkyl groups having from 1 to 5 carbon atoms. The compound in which X represents 8-hydroxy-1,2,3,4-tetrahydroisoquinolin-3-yl is named mureidomycin E and the compound in which X represents 6-hydroxy-1,2,3,4-tetrahydroisoquinolin-3-yl is named mureidomycin F. This group of compounds and their pharmaceutically acceptable esters and salts are useful as antibiotics for the treatment of bacterial infections.

Abstract: Novel compounds, called mureidomycins A, B, C and D, may be prepared by cultivation of a suitable microorganism of the genus Streptomyces, especially Streptomyces flavidovirens SANK 60486 (FERM P-8636, FERM BP-1347). These represent a wholly new class of antibiotics, which are valuable in the treatment of infections caused by a variety of bacteria, notably of the genus Pseudomonas.

Abstract: A new antibiotic having the chromophore structure of the plurmycin family of antibiotics is produced by fermentation of Streptomyces violaceus ATCC 53807. The new antibiotic designated BU-3839T, exhibits potent antibacterial activity and also inhibits the growth of tumors in experimental animal systems.

Abstract: An new antibiotic having the chromophore structure of the pluramycin family of antibiotics is produced by fermentation of Streptomyces violaceus ATCC 53807. The new antibiotic designated BU-3839T, exhibits potent antibacterial activity and also inhibits the growth of tumors in experimental animal systems.

Abstract: A new antibiotic having the chromophore structure of the pluramycin family of antibiotics is produced by fermentation of Streptomyces ciolaceus ATCC 53807. The new antibiotic designated BU-3839T, exhibits potent antibacterial activity and also inhibits the growth of tumors in experimental animal systems.